Viridian Therapeutics Inc
VRDN
Company Profile
Business description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Contact
221 Crescent Street
Suite 103A
WalthamMA02453
USAT: +1 617 272-4600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
143
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,456.20 | 90.50 | 1.08% |
CAC 40 | 7,770.48 | 176.61 | 2.33% |
DAX 40 | 23,086.65 | 589.67 | 2.62% |
Dow JONES (US) | 41,317.43 | 564.47 | 1.39% |
FTSE 100 | 8,596.35 | 99.55 | 1.17% |
HKSE | 22,504.68 | 385.27 | 1.74% |
NASDAQ | 17,977.73 | 266.99 | 1.51% |
Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
NZX 50 Index | 12,327.89 | 179.29 | 1.48% |
S&P 500 | 5,686.67 | 82.53 | 1.47% |
S&P/ASX 200 | 8,238.00 | 92.40 | 1.13% |
SSE Composite Index | 3,279.03 | 7.62 | -0.23% |